Spontaneous, recurrent spreading depolarizations (SD) are increasingly more appreciated as a pathomechanism behind ischemic brain injuries. Although the prostaglandin F2 -FP receptor signaling pathway has been proposed to contribute to neurodegeneration, it has remained unexplored whether FP receptors are implicated in SD or the coupled cerebral blood flow (CBF) response. We set out here to test the hypothesis that FP receptor blockade may achieve neuroprotection by the inhibition of SD.
Introduction
Spreading depolarization (SD), a remarkable neurophysiological phenomenon, has been recognized to be central to neurodegeneration after acute brain injury (Hartings et al., 2017) . Notably, recurrent
SDs have been associated with early focal brain injury and delayed ischemic neurological deficit after subarachnoid hemorrhage (Dreier et al., 2006; Hartings et al., 2017; Eriksen et al., 2019) , and may provoke unfavorable hemodynamic and metabolic conditions in the cerebral cortex of malignant hemispheric stroke patients (Woitzik et al., 2013; Pinczolits et al., 2017) .
SD corresponds to an abrupt, near complete breakdown of the transmembrane ion gradients and a near-complete sustained neuronal and glial depolarization that propagate in the cerebral gray matter at a slow rate (2 -8 mm/min) (Leao, 1944; Somjen, 2001) . The restoration of the membrane potential requires the mobilization of metabolic resources for the operation of ATP-dependent ion pumps (e.g.
the Na + /K + ATP-ase). This need is met by a profound hyperemic cerebral blood flow (CBF) response coupled to SD in otherwise non-compromised tissue (Ayata and Lauritzen, 2015) . The coupling between SD and local CBF becomes impaired under ischemia, which may create a metabolic supply-demand mismatch, a subsequent energy crisis superimposed on prevailing ischemia, and facilitated tissue injury (Dreier, 2011) .
The current understanding of the relevance of SD in acute brain injuries posits that SD is harmful because its recurrence imposes an overwhelming metabolic challenge and triggers excitotoxicity in ischemic brain tissue (Hartings et al., 2017; Shuttleworth et al., 2019) . Consequently, the suppression of SD, or the improvement of the hemodynamic response to SD have been considered as therapeutic approaches in the post-operative care of brain injury patients (Helbok et al., 2019) . Appreciating the cellular mechanisms of neurodegeneration triggered by SD (Hertelendy et al., 2019) , the pharmacological modulation of SD has targeted (i) NMDA receptor-based glutamate excitotoxicity with vasoconstriction, and thereby impede neuronal survival under penumbra-like ischemic conditions. To test the hypotheses, we carefully analyzed the characteristics of SD and the coupled CBF response under pharmacological FP receptor antagonism in comparison with control conditions in the ischemic rat brain.
Then, the degree of ischemia/reperfusion injury was evaluated with immunocytochemistry in perfusionfixed brain slices of the animals. Also, we set out to identify which distinct elements of the nervous tissue carry FP receptors, to confirm potential sites of action. Taken together, the ultimate purpose of this study has been to evaluate the protective potential of FP receptor antagonism against SD and the related neurodegeneration.
Materials and Methods

Animals
The The designed rate of the two groups (untreated and treated) was 1. The necessary number of animals in each group was at least 7 to support 80% power (β=20% risk of second species), which was calculated based on the standard deviation of electrophysiological and hemodynamic parameters in earlier studies and the presumed differences between the means of the two groups. The calculations feedback-controlled heating pad (Harvard Apparatus, USA). Atropine was administered (0.1 %, 0.05 ml;
i.m) as premedication in order to avoid the production of airway mucus. Mean arterial blood pressure (MABP) and heart rate were monitored with a Mikro-Tip pressure catheter inserted to the left femoral artery (Mikro-Tip BP Foundation System, ADInstruments, Australia). The adjacent femoral vein was cannulated for drug administration. The respiratory rate was monitored with a piezo-electric pulse transducer (Pulse Transducer (DIN), ADInstruments, Australia) attached to the chest of the animal. For the later initiation of incomplete global forebrain ischemia, a midline incision was made in the neck and each common carotid artery was carefully looped around with a surgical thread. Lidocaine (1%) was used for local anesthesia. All rats were fixed by their head in a prone position in a stereotaxic apparatus.
The scalp was opened, and the temporal muscle was gently retracted from the temporal bones. Two adjacent craniotomies (5 mm lateral from the sagittal suture, -1, -5 caudal from the bregma) were prepared on the right parietal bone with a dental drill (ProLab Basic, Bien Air 810, Switzerland) ( Fig. 1 ).
The dura was then carefully opened in each craniotomy. The caudal window was used for electrophysiological monitoring, while the rostral window served SD elicitation. The cranial windows were constantly kept moist by artificial cerebrospinal fluid (aCSF; mM concentrations: 126.6 NaCl, 3 KCl, 1.5 CaCl 2 , 1.2 MgCl 2 , 24.5 NaHCO 3 , 6.7 urea, 3.7 glucose bubbled with 95 % O2 and 5 % CO2 to achieve a constant pH of 7.4). The rest of the bone was thinned, including the medial part of the contralateral parietal bone ( Fig. 1 ) in order to visualize CBF changes with laser speckle contrast imaging (LSCI) (PeriCam PSI HR, Perimed AB, Sweden).
Two of the rats were excluded because they developed respiratory failure under anesthesia and died as a consequence during the experimental protocol. One additional animal was terminated before the beginning of the experimental protocol because the preparation of the cranial window caused extensive hemorrhage. This resulted in group sizes of 7 and 8 rats, AL-8810-treated and control, respectively.
Recording of electrophysiological variables and imaging of cerebral blood flow
For the acquisition of the electrocorticogram (ECoG) and slow cortical or direct current (DC) potential, a saline-filled (120 mM NaCl) glass capillary microelectrode ( 
Experimental protocol
After 10 minutes of baseline period, both common carotid arteries were occluded (2-vessel occlusion, 2VO) by pulling and securing the surgical threads looped around the vessels. Successful 2VO was confirmed by a sharp drop of CBF. The FP-receptor antagonist AL-8810 (1 mg/bwkg, dissolved in 0.1 % dimethyl sulfoxide in physiological saline, Sigma-Aldrich, USA) or its vehicle were bolus administered i.v. in 1 ml volume 10 minutes after 2VO onset (Fig. 1 ). The dose of AL-8810 was selected to correspond to a dose found effective to reduce ischemic brain infarct volume in a previous experimental study, where AL-8810 was injected i.v. at 1 or 10 mg/bwkg (Kim et al., 2012) . Since the lower concentration was found effective (Kim et al., 2012) , and lower drug concentrati ons are expected to deliver potential side effects less likely, we designed our experiments accordingly. SDs were triggered Journal Pre-proof albumin (BSA) for 1 h at room temperature. Slices were incubated with primary antibodies overnight at 4°C (anti-cleaved caspase-3: rabbit, Cell Signaling, #9661, 1:500; anti-GFAP: mouse, Sigma, G3893, 1:10000; anti-NeuN: mouse, Millipore, MAB377, 1:500; in 1% BSA in PBS). Secondary antibodies were applied for 1 h at room temperature (anti-rabbit Alexa 594; goat, Jackson Laboratories, 1:500; antimouse Alexa 488, goat, Jackson Laboratories, 1:500; in 1 % BSA in PBS). Slices were mounted with Fluoromount-G with DAPI (Thermo Fisher Scientific, USA), for the additional visualization of cell nuclei.
Representative photomicrographs were taken of the somatosensory cortex of a control animal with a Leica SP5 inverted laser scanning confocal microscope (TE2000U, Leica Microsystems GmbH, Germany) with 63x objective with additional digital zoom giving. Confocal images were pieced together and processed in ImageJ.
Finally, in order to identify the cellular and subcellular localization of FP receptors, the receptors were co-labeled with NeuN (neuronal marker), GFAP (astrocyte marker), Iba1 (microglia marker), claudin-5 (endothelial cell marker) or alpha-actin (vascular smooth muscle cell marker) in slices from a naïve animal. Antigens were retrieved with 10-minute-long boiling in citrate buffer (pH 5; 95°C, shaking at 300 rpm) for claudin-5 co-staining. All slices were permeabilized with 0.2 % Triton X-100 in PBS for 30 minutes. Non-specific protein-binding sites were blocked with 3 % BSA for 1 h at room temperature.
Slices were incubated with primary antibodies overnight at 4 °C (anti-FP receptor: rabbit, Abcam, ab203342, 1:100; anti-NeuN: mouse, Millipore, MAB377, 1:500; anti-GFAP: mouse, Sigma, G3893, 1:10000; anti-Iba-1: goat, Abcam, ab48004, 1:500; anti-claudin-5: mouse, Invitrogen, #4C3C2, 1:100; in 1% BSA in PBS; anti-α-smooth muscle actin, GeneTex, GTX73419, ready-to-use). Secondary antibodies were applied for 1 h at room temperature (anti-rabbit STAR RED; goat, Abberior, 1:500; anti-mouse STAR 580, goat, Abberior, 1:500; anti-goat Alexa-594, donkey, Thermo Fisher Scientific, 1:500; in 1% BSA in PBS). In case of Iba-1 and FP double staining, the incubation with anti-goat secondary antibody was followed by the incubation with goat anti-rabbit antibody to avoid cross-reaction. Slices were mounted with Fluoromount-G (Thermo Fisher Scientific). Representative confocal images were taken of the somatosensory cortex with a Zeiss Axio Observer Z1 inverted microscope (Carl Zeiss GmbH, Germany), and pieced together and processed in ImageJ (National Institutes of Health, Bethesda, Maryland, USA).
Data analysis
Physiological variables (i.e. DC potential and MABP) were simultaneously acquired, displayed live, and stored using a personal computer equipped with the software LabChart 8 (ADInstruments, Australia). the LSCI signal was acquired with PeriFlux System 5000 (Perimed AB, Sweden) and displayed J o u r n a l P r e -p r o o f Journal Pre-proof live with PIMSoft. Raw LSCI recordings were downsampled to 1 Hz before analysis. All data were then converted and analyzed with the inbuilt instructions of the software AcqKnowledge 4.2 for MP 150 (Biopac Systems, Inc., USA).
Blinding data analysis was intended by assigning codes to files and recordings, which do not reveal the experimental condition (i.e., date of the experiment). The SD events were first sorted according to their duration and amplitude: With reference to regular transient SDs, prolonged SDs were noted when the depolarization was longer than 3 min while the amplitude of the depolarization was similar to transient SDs (>10 mV), and incomplete SDs were identified by their amplitude smaller than 10 mV, and their duration shorter than 30 s (Fig 2A) . For all SD events, peak amplitude, duration at half amplitude, the rate of depolarization and repolarization, and area under the curve (AUC) were measured on the DC potential trace. The distribution of spectral power of the ECoG recordings at alpha (8-13Hz) and delta (1-4Hz) frequency bands were done with the software LabChart Pro (Labchart 8, National Instrument, Australia). Total power for each frequency band was expressed for 60-s periods taken (i) before the induction of cerebral ischemia, (ii) before the controlled elicitation of the 1st SD, (iii) before continuous SD elicitation, and (iv) after reperfusion. As a proxy for latter lesion formation, alpha-to-delta ratio (ADR) was calculated for each time points (Menyhárt et al., 2015) . SD frequency was also calculated for recurrent events under continuous elicitation. (Menyhárt et al., 2015; Lückl et al., 2018) . The treatment with AL-8810 did not exert any detectable impact on the examined variables (Table 1) .
AL-8810 reduced depolarization time and promoted early recovery after SD
The occurrence of SD clusters or prolonged depolarizations, and the long cumulative duration of recurrent SDs indicate and predict the development of secondary ischemic brain injury after an acute insult (Dreier et al., 2006; Hartings et al., 2017; Shuttleworth et al., 2019) . We have demonstrated earlier that the inhibition of the EP4 receptor of PGE2 causes the unfavorable elongation of SD in the ischemic cerebral cortex (Varga et al., 2016) . Here we explored whether the antagonism of the FP receptor of PGF2 modulates the occurrence or duration of SDs beneficially.
SD occurrence was confirmed with electrophysiology and LSCI in the ipsilateral cortex, but no SD propagation to the contralateral side was seen in the CBF maps. In case of the initial, controlled elicitation, all SDs were transient with no statistical difference in the DC potential signature between the two groups (i.e. amplitude: -18.3±2.7 vs. -18.0±2.6 mV, AL-8810 vs. vehicle; duration at half amplitude:
55±25 vs. 56±19 s, AL-8810 vs. vehicle).
Subsequent to controlled SD elicitation, clusters of SDs were triggered with continuous KCl exposure.
Each of these recurrent SDs was categorized as transient, prolonged or incomplete, on the basis of their DC potential signature acquired at the implanted electrode ( Fig. 2A) . Then their incidence relative to the total number of recurrent SDs was expressed for the AL-8810 and the vehicle-treated groups separately Detailed, quantitative analysis of recurrent SDs focused on transient events (Fig 3) . Similar to the controlled SDs, the amplitude of the clustered SDs was similar in the two experimental groups (-17.5±2.4
vs. -16.9±3.1 mV, AL-8810 vs. vehicle). Nevertheless, AL-8810 treatment accelerated the repolarization after SDs (0.84±0.4 vs. 0.45±0.22 mV/s, AL-8810 and vehicle) ( Fig 3A 1 ) . Accordingly, the average duration of an SD at half amplitude (30±10 vs. 56±14 s, AL-8810 vs. vehicle) ( Fig. 3A 2 ) , as well as the cumulative duration of recurrent transient SDs was found shorter (304±71 vs. 577±154 s, AL-8810 vs. vehicle) in the AL-8810-treated compared to the control group. In line with these data, the magnitude of individual SDs expressed as AUC was reduced in the AL-8810 treated group compared to control (585±192 vs. 942±251 mV*s; AL-8810 vs. vehicle) ( Fig 3A 3 ). Taken together, FP receptor blockade prevented the development of prolonged depolarization, accelerated repolarization, and shortened the cumulative duration of clustered, recurrent SDs.
AL-8810 increased electrocorticographic alpha-to-delta ratio in the reperfused cortex
Lowering electrocorticographic alpha-to-delta ratio (alpha power/delta power, ADR) has been proposed as a sensitive and selective tool to predict the evolution of delayed cerebral ischemia after aneurismal subarachnoid hemorrhage (Claassen et al., 2004; Rots et al., 2016; Yu et al., 2019) . In addition, delayed cerebral ischemia has been linked to SD (Dreier et al., 2006; Dreier et al., 2009 ) .
Therefore, we calculated ECoG power for alpha (8-13Hz) and delta (1-4Hz) frequency bands and expressed ADR for 4 selected time points over the experimental protocol ( Fig. 3B 1 The CBF response to SD consists of at least three distinct elements including a brief, early hypoperfusion, a subsequent, substantial hyperemia, and a final, long lasting oligemia (Ayata and Lauritzen, 2015) . The pharmacological augmentation of the CBF response to SD in the service of neuroprotection is a realistic goal, because insufficient hyperemia and especially the occurrence of spreading ischemia (i.e. the early hypoperfusion element of the CBF response overriding the hyperemic component) delays repolarization and reduces the viability of penumbra tissue (Dreier, 2011; Hartings et al., 2017 JCBFM) .
The spatial resolution offered by LSCI in our experiments enabled a comprehensive analysis of the CBF response to SD. We concentrated our detailed analysis on recurrent SDs, which emerged as regular, transient negative DC potential shifts (amplitude > 10 mV, duration < 3 min) at the electrode implanted.
First, with the aid of placing multiple regions of interest (ROIs) on the CBF videos ( Fig. 4A ), we noted that the kinetics of the CBF response associated to a given SD may alter over the course of SD propagation.
Hyperemic Together these data demonstrate that AL-8810 treatment increased CBF in the ischemic cerebral cortex, and counteracted transient CBF reduction with SD.
J o u r n a l P r e -p r o o f
AL-8810 treatment salvaged SD triggered apoptosis in the cortex, but exerted no impact on microglia activation
Cleaved caspase-3 (CC3) has been a widely accepted apoptosis marker in the nervous tissue (Fricker et al., 2018) , which can be detected confidently 3 hours after the onset of reperfusion (Davoli et al., 2002 , Manabat et al., 2003 .
Accordingly, we collected brain samples 3 hours after the initiation of reperfusion to assess the neuroprotective potential of AL-8810. CC3-positive apoptotic cells were observed in striatal, hippocampal and cortical areas in both experimental groups, albeit to a lesser degree in the AL-8810treated animals ( Fig. 5A-B 1 ) . The immunofluorescent co-localization of CC3 with NeuN and GFAP revealed that both neurons and astrocytes were engaged in apoptosis ( Fig. 5B 2 ) . With the anticipation of more extensive apoptosis in the hemisphere ipsilateral to SD elicitation, the number of CC3immunopositive cells was normalized to the contralateral side. The quantitative approach suggested a significant neuroprotective effect of AL-8810 shown by the reduction of CC3 positive cell numbers in the ipsilateral relative to the contralateral hemisphere (e.g. somatosensory and occipital cortices:
94.4±12.6% vs. 112.9±7.0 %; 104.3±17.6 % vs. 125,7±17,7 %, respectively, AL-8810 vs. vehicle) (Fig. 5C ).
Overall, AL-8810 treatment appeared to offer detectible neuroprotection measured early after ischemia/reperfusion induction.
Microgia activation is a rapid neuro-inflammatory response to injury, which was previously suppressed with AL-8810, assessed days after experimental traumatic brain injury (Glushakov et al., 2013) . We have observed intensive Iba1 immuno-labeling in the tissue samples (Fig. 5D ). While the number of labeled microglia was similar in the two hemispheres irrespective of treatment (317 and 286, contra-and ipsilateral), their arborization was less dense in the ipsilateral hemisphere indicative of their increased activation (ramification index: 112.755.4 vs. 174.273.8, ipsi-vs. contralateral). The administration of AL-8810 did not exert any discernable impact on the ramification of microglia processes (ramification index: 148.663.8 and 138.380.3, control and AL-8810) ( Fig. 5D-E) .
The co-localization of FP receptors with NeuN and GFAP confirmed the localization of FP receptors predominantly in the nuclear envelope of neurons (Fig. 6A) , as well as in the perikaryon and perivascular endfeet of astrocytes ( Fig. 6B 1-2 ). In addition, we observed a robust co-localization of FP receptors with Iba1-labeled microglia (Fig. 6C) . The presence of FP receptors was also obvious in claudin-labeled cerebromicrovascular endothelial cells. However, we were not able to detect FP receptors unequivocally in -actin-labeled cerebrovascular smooth muscle cells. In summary, FP receptor expression has been confirmed in both neuronal, glial and vascular elements in the rat brain.
Discussion
Here we have explored the neuroprotective potential of the antagonism of the PGF2 FP receptor in experimental global forebrain ischemia/reperfusion exacerbated by recurrent SDs.
Prostaglandin signaling has been in the center of pharmaceutical research for decades. Importantly, experimental research suggested that cyclooxygenase-2 enzyme (COX-2) inhibition may have therapeutic potential in stroke (Candelario-Jalil and Fiebich, 2008) . However, the controversial action of repetitively administered COX-2 inhibitors on platelet function may manifest in cardiovascular adverse effects including thrombus formation and heart failure (Santilli et al., 2016) . In particular, in the context of ischemic brain injury, the use of COX-2 inhibitors prior to the occurrence of ischemic stroke was associated with worse stroke outcome in patients (Schmidt et al., 2014) . Since COX-2 inhibition suppresses the synthesis of all types of prostaglandins downstream to the enzyme ( e.g. PGE2, PGF2, thromboxanes), and each prostaglandin may act on a number of receptor types mediating complementary or opposing actions, subsequent efforts focused on the selective modulation of distinct prostaglandin receptors. Indeed, the EP1-EP4 receptors of PGE2 have been intensively studied and a wealth of experimental data on their implication in ischemic brain injury have been gathered (Andreasson, 2010) . In the context of SD, EP4 receptors appeared to be involved in the repolarization phase of SD in the ischemic rodent brain (Varga et al., 2016 ). Yet, the FP receptor of PGF2 appears to have received considerably less attention (Zhang et al., 2010; Sharif and Klimko, 2019) , even though PGF2 concentration was elevated in the brain tissue and the cerebrospinal fluid in animal models of cerebral ischemia or SD (Gaudet and Levine, 1980; Katz et al. 1988; Shibata et al., 1992) , and PGF2
immunolabeling was found enhanced after cerebral ischemia/reperfusion in the cerebral vascular wall and hippocampal neurons of rats (Ogawa et al., 1987) .
J o u r n a l P r e -p r o o f
Our data demonstrate that the antagonism of the PGF2 FP receptors suppressed SD in the ischemic rat cerebral cortex (Fig. 2) , reduced the duration of recurrent SDs by facilitating repolarization, and augmented the recovery of ECoG during reperfusion (Fig. 3) . Parallel with the neurophysiological actions, FP receptor antagonism improved perfusion in the ischemic cerebral cortex, and attenuated hypoemic CBF responses associated with SD (Fig. 4) . Further, FP receptor antagonism appeared to curtail apoptotic cell death related to SD recurrence (Fig. 5) . Collectively, these findings are in agreement with a number of previous reports of a research group, which presented that the pharmacological antagonism or genetic knock-out of FP receptors reduced ischemic infarct volume and improved functional outcome in preclinical models of ischemic or traumatic brain injury (Saleem et al., 2009; Kim et al., 2012; Glushakov et al., 2013) . Since spontaneous, recurrent SDs of long cumulative duration have been strongly implicated in the pathophysiology of ischemic or traumatic brain injury (Dreier et al., 2006; Hartings et al., 2017) , it is plausible that the facilitated recovery from SD achieved with FP receptor antagonism -as shown here -could have contributed to reduced lesion volume and less severe functional deficit registered in the previous studies.
The ability of the nervous tissue to repolarize after SD is subject to the metabolic status of the brain region involved in SD evolution. The increasing severity of ischemia -and thus energy depletion of the tissue -leads to sodium pump dysfunction and the failure of active ion translocation between the intraand extracellular compartments, and delays the recovery of the resting membrane potential once SD has occurred (Dreier, 2011) . Since FP receptor antagonism in our experiments markedly improved the perfusion of the ischemic cerebral cortex (Fig. 4) , it is conceivable that SD duration was shortened in the AL-8810-treated animals (Fig. 3) because the tissue was metabolically less compromised. Indeed, FP receptors at the periphery have been previously implicated in the regulation of vascular tone (Zhang et al., 2010) . FP receptors were associated with cultured smooth muscle cells of a cell line derived from the embryonic rat aorta (Rice et al, 2008) , and the smooth muscle cells of preglomerular arterioles in the kidney (Yu et al., 2009) . The presence of FP receptors on vascular smooth muscle cells was suggested to be the anatomical basis for FP receptor linked vasoconstriction (Zhang et al., 2010) . In addition to vascular smooth muscle cells, venous endothelial cells of the peripheral vascular network were also found to express FP receptors, which mediated PGF2-related vasorelaxation of the jugular and submental veins or constriction of the human umbilical vein (Chen et al., 1995; Astin and Stjernschantz, 1997; Zannoni et al., 2007) . Finally, membranes prepared from porcine cerebral microvessels were shown to host FP receptors (Li et al., 1994) , and PGF2 applied to baboon isolated middle cerebral artery rings was demonstrated to cause dilation at lower, and constriction at higher concentration J o u r n a l P r e -p r o o f Journal Pre-proof (Hayashi et al., 1985) . We have identified FP receptors associated with endothelial cells and perivascular astrocytic endfeet of the neurovascular unit (Fig. 6 ), located at an ideal position to contribute to cerebrovascular tone adjustment. Considering the experimental data accumulated on PGF2-FP receptor signaling in various vascular domains (Zhang et al., 2010) , AL-8810 treatment in our study is suggested to have targeted -in part -the FP receptors identified at elements of the neurovascular unit ( Fig. 6) . FP receptor antagonism with AL-8810 presumably counteracted PGF2-linked vasoconstrictive tone, and, consequently, improved cerebrocortical blood flow (Fig. 4) .
Spreading ischemia coupled to SD that propagates across vulnerable penumbra tissue has been considered particularly harmful (Dreier et al., 1998; Dreier, 2011; Hartings et al., 2017) . We have observed a few events of spreading ischemia near the site of SD elicitation, which transformed to hyperemic CBF response along the direction of SD propagation, with the increasing distance from the SD focus ( Fig. 4B ). Spreading ischemia occurred near the site of SD elicitation possibly because of the close proximity of the local administration of high concentration KCl to evoke SDs, which has been shown to potentiate SD-related hypoperfusion (Menyhárt et al., 2018) . The occurrence of spreading ischemia was less frequent under AL-8810 treatment, and flow reduction with the observed events in the AL-8810 group was considerably attenuated (Fig. 4E ). This is considered as additional evidence for the vasoconstrictive role cerebrovascular FP receptors may fulfill in the mediation of the CBF response to SD.
The pharmacological inhibition of the FP receptors in our experiments could have contributed to neuroprotection (Fig. 5) by targeting neurons directly, as well. We have observed conspicuous FP receptor labeling co-localized with neurons ( Fig. 6A) , which is consistent with previous work that revealed the presence of FP receptors in synaptosome preparations or cultured neurons (Li et al., 1993; Kim et al., 2012) . In support of the notion of direct neuroprotection by FP receptor antagonism, AL-8810 proved to sustain the viability of cultured neurons exposed to oxygen-glucose deprivation (OGD), reduced the production of reactive oxygen species in OGD-stressed hippocampal slices, and suppressed the OGD-induced rise of intraneuronal Ca 2+ concentration (Kim et al., 2012) . It is noteworthy that intracellular Ca 2+ concentration increases considerably with SD itself, and may prove deleterious to neurons (Dietz et al., 2009) . The Ca 2+ overload with SD was previously prevented by the NMDA receptor antagonist ketamine . In addition, the L-type voltage-gated Ca 2+ channel blocker nimodipine shortened SD duration similar to that achieved with ketamin M. Tóth et al., 2019) . Therefore, it may well be, that a potential reduction of intracellular Ca 2+ content by AL-8810 -as shown in neuronal cell culture (Kim et al., 2012) -could have contributed J o u r n a l P r e -p r o o f directly to shortened SD duration (Fig. 3) , and the limitation of SD-related apoptosis (Fig. 5) as seen here.
The impact of AL-8810 treatment on microglia was evaluated here, as well, because microglia were found to be richly endowed with FP receptors (Fig. 6C) . Previously, cultured rat microglia were shown not to express FP receptor mRNA (Kitanaka et al., 1996) , yet, later investigation identified functional FP receptors on transformed human brain microglial cells (Xu et al., 2009) . Further, in a model of experimental TBI, AL-8810 administration attenuated microglia proliferation days after the primary impact (Glushakov et al., 2013) . In our experiments, microglia activation proved to be enhanced in the cortex ipsilateral to SD recurrence and the open cranial window, in addition to that caused by ischemia alone. Our previous data have shown that the surgical procedure itself (i.e. craniotomy) causes microglia activation, and recurrent SDs enhance it further (M. , which amounts to the difference observed between the ipsi-and contralateral hemispheres in our preparations ( Fig. 5D-E) .
AL-8810 did not alter microglia activation at this time point after the primary insult (i.e. 5 hours after ischemia onset, and 3 hours after the occurrence of recurrent SDs). This suggests that even though microglia abundantly express FP receptors (Fig. 6C ), these may not be functionally linked to microglia activation by endogenous PGF2 in the acute/subacute phase of cerebral ischemia.
Recurrent SDs propagating over cerebrocortical zones under metabolic stress have been increasingly more appreciated as the electrophysiological correlate of and pathophysiological contributor to ischemic injury progression (Dreier, 2011; Hartings et al., 2017) . Options for the pharmacological restriction of SD occurrence in acute brain injury patients have been, therefore, explored and debated intensively (Carlson et al., 2018; Sugimoto et al., 2018; Carlson et al., 2019; Helbok et al., 2019) . The clinical evidence gathered so far supports the inhibition of SD with the non-selective NMDA receptor antagonist and sedative agent ketamine (Hertle et al., 2012; Carlson et al., 2018) , and experimental research has identified the L-type voltage-gated Ca 2+ channel blocker nimodipine, as an additional, promising candidate for SD restriction (Dreier et al., 2002; Carlson et al., 2019; Szabó et al., 2019; M. Tóth et al., 2019) . Our current experiments together with our previous results (Varga et al., 2016) suggest that prostaglandin signaling may be considered as an alternative or complementary target for intervention with therapeutic potential. After a period of reperfusion, the brains were removed for histological examination. The number of events analyzed is indicated in each bar. Data are given as mean±stdev. A two-way ANOVA model (factors: ischemia and treatment) was used for statistical analysis. Ischemia was found to increase blood pressure and arterial pO 2 significantly (p<0.05*). Abbreviations: 2VO, permanent, bilateral occlusion of the common carotid arteries ("two-vessel occlusion"); BPM, beat per minute; MABP: mean arterial blood pressure.
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